Lonza Group Ltd today celebrates the groundbreaking of the new facility for its Cell Therapy business, located at Tuas Biomedical Park in Singapore and adjacent to Lonza’s large-scale mammalian manufacturing facility.
The event was officiated by Mr S Iswaran, Senior Minister of State for Trade & Industry and Education.
In his welcome address to celebrate the groundbreaking ceremony, Stefan Borgas, CEO of Lonza, said: “This new Cell Therapy manufacturing facility is a next step in fulfilling our strategy to expand our capacity globally and our presence in Asia. Cell Therapy is expected to be one of the most important innovation drivers of modern medicine and this new facility reinforces Lonza’s leading position as a custom manufacturer of cellular therapeutics”.
The construction of the Cell Therapy manufacturing facility was initiated in May 2009. Construction will begin early in 2010 and the facility is expected to begin manufacturing therapies within the first two suites by mid-2011. The facility is designed to accommodate additional suites built to meet incremental customer demand. The total investment for the first phase will be approximately CHF 30 million.
Speaking at the groundbreaking ceremony, Mr S Iswaran, Senior Minister of State for Trade & Industry and Education, Singapore, said: “We are pleased to be working with Lonza, the leading industry contract manufacturer for globally trusted cellular therapeutics. Lonza’s decision to site beach-head investments in Singapore will enhance our strong foundation in cell therapy and strengthen our position as a home-base for companies’ pioneering investments in Asia.”
Cellular-based therapeutics promise to address many unmet medical needs across many disease categories. Lonza, with twelve existing cGMP-certified cell therapy manufacturing suites in the USA and Europe, is uniquely positioned to provide full custom manufacturing support for this type of therapy worldwide.
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers’ needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.
Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange. In 2008, Lonza had sales of CHF 2.937 billion. Further information can be found at www.lonza.com.
For further Information:
Lonza Group Ltd
Head Corporate Communications
Tel +41 61 316 8624
Fax +41 61 316 9624
Lonza Group Ltd
Tel +41 61 316 8798
Fax +41 61 316 9798
Lonza Group Ltd
Tel +41 61 316 8835
Fax +41 61 316 9835